|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.69 USD | -0.73% |
|
+0.66% | +5.40% |
| Jul. 30 | Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US | RE |
| Jul. 30 | GSK global supply chain director sells 38,000 shares | AN |
| Market Cap | 77.4B 104B 90.57B 84.3B 146B 9,945B 148B 994B 390B 4,951B 391B 383B 16,602B | P/E 2026 * |
12.7x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 95.16B 128B 111B 104B 180B 12,228B 182B 1,222B 479B 6,088B 481B 471B 20,413B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.56x |
| Free-Float |
92.75% | Yield 2026 * |
3.6% | Yield 2027 * | 3.79% |
Last Transcript: GSK plc
| Jul. 30 | GSK : Deutsche Bank gives a Neutral rating | ZD |
| Jul. 30 | Berenberg raises Rio Tinto; HSBC ups Centrica | AN |
| Jul. 30 | Goldman Sachs still cautious about GSK |  |
| Jul. 29 | GSK : DZ Bank remains Neutral | ZD |
| Jul. 29 | GSK : JP Morgan reaffirms its Sell rating | ZD |
| 1 day | -0.73% | ||
| 1 week | +0.66% | ||
| 1 month | +0.76% | ||
| 3 months | +0.16% | ||
| 6 months | +0.17% | ||
| Current year | +5.40% |
| 1 week | 51.38 |  | 55.78 |
| 1 month | 49.89 | | 55.78 |
| Current year | 47.62 | | 61.7 |
| 1 year | 36.75 | | 61.7 |
| 3 years | 31.72 | | 61.7 |
| 5 years | 28.46 | | 61.7 |
| 10 years | 28.46 | | 61.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73% | +0.66% | - | - | 104B | |
| -0.53% | -3.95% | +50.70% | +153.56% | 1,024B | |
| +0.21% | -2.68% | +53.20% | +51.79% | 618B | |
| -2.51% | -3.25% | +28.54% | +68.94% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.69% | -0.30% | +13.76% | +12.83% | 264B | |
| -7.37% | -4.40% | -0.74% | -44.28% | 209B | |
| -0.64% | +2.43% | +29.74% | +65.93% | 208B | |
| -0.82% | +0.70% | +15.05% | +72.05% | 162B | |
| +0.40% | +1.92% | +6.47% | -29.77% | 143B | |
| Average | -1.26% | -1.21% | +26.03% | +42.41% | 379.88B | |
| Weighted average by Cap. | -1.00% | -2.02% | +36.14% | +71.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.97B 45.73B 39.75B 37B 64.15B 4,365B 65.14B 436B 171B 2,173B 172B 168B 7,287B | 35.62B 47.95B 41.68B 38.79B 67.26B 4,577B 68.3B 457B 179B 2,279B 180B 176B 7,641B |
| Net income | 6.14B 8.26B 7.18B 6.69B 11.59B 789B 11.77B 78.81B 30.93B 393B 31.03B 30.35B 1,317B | 6.96B 9.37B 8.14B 7.58B 13.14B 894B 13.34B 89.33B 35.06B 445B 35.18B 34.4B 1,493B |
| Net Debt | 17.76B 23.91B 20.79B 19.35B 33.55B 2,283B 34.07B 228B 89.51B 1,136B 89.81B 87.84B 3,811B | 13.64B 18.37B 15.97B 14.86B 25.76B 1,753B 26.16B 175B 68.75B 873B 68.97B 67.46B 2,927B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-31 | $51.69 | -0.73% | 3,982,166 |
| 26-07-30 | $52.07 | -2.16% | 6,110,522 |
| 26-07-29 | $53.22 | -0.91% | 6,309,737 |
| 26-07-28 | $53.71 | +3.33% | 8,292,871 |
| 26-07-27 | $51.98 | +1.23% | 5,503,300 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
